Rejection rates in a randomised trial of tacrolimus monotherapy versus triple therapy in liver transplant recipients with hepatitis C virus cirrhosis

Transplant Infectious Disease

Volumn 8, Issue 1, 2006, Pages 3-12

  Samonakis, D N ^a   Mela, M ^a   Quaglia, A ^a   Triantos, C K ^a   Thalheimer, U ^a   Leandro, G ^a   Pesci, A ^a,b   Raimondo, M L ^a   Dhillon, A P ^a   Rolles, K ^a   Davidson, B R ^a   Patch, D W ^a   Burroughs, A K ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b SACRO CUORE DON CALABRIA HOSPITAL   (Italy)

Author keywords

Cirrhosis; Hepatitis C; Liver transplantation; Randomised trial; Tacrolimus monotherapy

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; STEROID; TSUKUBAENOLIDE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; EMPIRICISM; FEMALE; FREQUENCY ANALYSIS; GRAFT RECIPIENT; HEPATITIS C VIRUS; HISTOPATHOLOGY; HUMAN; KIDNEY DYSFUNCTION; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NEUROTOXICITY; NEUTROPENIA; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RETRANSPLANTATION; STATISTICAL SIGNIFICANCE; STEROID THERAPY; SURGICAL MORTALITY; TREATMENT DURATION; TREATMENT INDICATION;

ADULT; AGED; AZATHIOPRINE; DRUG THERAPY, COMBINATION; FEMALE; GRAFT REJECTION; HEPATITIS C; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PREDNISOLONE; RECURRENCE; SURVIVAL ANALYSIS; TACROLIMUS; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 33645708914     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/j.1399-3062.2006.00124.x     Document Type: Article

References (46)

1. Riordan SM Williams R. Tolerance after liver transplantation does it exist and can immunosuppression be withdrawn? J Hepatol 1999 31 1106 1119.
2. International Working Party. Terminology for hepatic allograft rejection. Hepatology 1995 22 648 654.
3. Hubscher S. Diagnosis and grading of liver allograft rejection a European perspective. Transplant Proc 1996 28 504 507.
4. Neuberger J Wilson P Adams D. Protocol liver biopsies the case in favour. Transplant Proc 1998 30 1497 1499.
5. Wiesner RH. Is hepatic histology the true gold standard in diagnosing acute hepatic allograft rejection? Liver Transpl Surg 1996 2 165 167.
6. Banff schema for grading liver allograft rejection an international consensus document. Hepatology 1997 25 658 663.
7. Datta GS Hudson M Burroughs AK et al. Grading of cellular rejection after orthotopic liver transplantation. Hepatology 1995 21 46 57.
8. Tippner C Nashan B Hoshino K et al. Clinical and subclinical acute rejection early after liver transplantation contributing factors and relevance for the long-term course. Transplantation 2001 72 1122 1128.
9. Wiesner RH Demetris AJ Belle SH et al. Acute hepatic allograft rejection incidence, risk factors, and impact on outcome. Hepatology 1998 28 638 645.
10. Raimondo ML Burroughs AK. Single-agent immunosuppression after liver transplantation what is possible? Drugs 2002 62 1587 1597.
11. Eason JD Nair S Cohen AJ Blazek JL Loss GE Jr.. Steroid-free liver transplantation using rabbit antithymocyte globulin and early tacrolimus monotherapy. Transplantation 2003 75 1396 1399.
12. Langrehr JM Neumann UP Lang M et al. First results from a prospective randomized trial comparing steroid-free induction therapy with tacrolimus and MMF versus tacrolimus and steroids in patients after liver transplantation for HCV. Transplant Proc 2002 34 1565 1566.
13. Pirenne J Aerts R Koshiba T et al. Steroid-free immunosuppression during and after liver transplantation - a 3-yr follow-up report. Clin Transplant 2003 17 177 182.
14. Rolles K Davidson BR Burroughs AK. A pilot study of immunosuppressive monotherapy in liver transplantation tacrolimus versus microemulsified cyclosporin. Transplantation 1999 68 1195 1198.
15. Berenguer M Prieto M Cordoba J et al. Early development of chronic active hepatitis in recurrent hepatitis C virus infection after liver transplantation association with treatment of rejection. J Hepatol 1998 28 756 763.
16. Berenguer M Crippin J Gish R et al. A model to predict severe HCV-related disease following liver transplantation. Hepatology 2003 38 34 41.
17. Sheiner PA Schwartz ME Mor E et al. Severe or multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantation. Hepatology 1995 21 30 34.
18. Singh N Gayowski T Ndimbie OK Nedjar S Wagener MM Yu VL. Recurrent hepatitis C virus hepatitis in liver transplant recipients receiving tacrolimus association with rejection and increased immunosuppression after transplantation. Surgery 1996 119 452 456.
19. O'Grady JG Burroughs A Hardy P Elbourne D Truesdale A. Tacrolimus versus microemulsified ciclosporin in liver transplantation the TMC randomised controlled trial. Lancet 2002 360 1119 1125.
20. Scott LJ McKeage K Keam SJ Plosker GL. Tacrolimus a further update of its use in the management of organ transplantation. Drugs 2003 63 1247 1297.
21. Papatheodoridis GV Davies S Dhillon AP et al. The role of different immunosuppression in the long-term histological outcome of HCV reinfection after liver transplantation for HCV cirrhosis. Transplantation 2001 72 412 418.
22. Papatheodoridis GV Patch D Watkinson A Tibballs J Burroughs AK. Transjugular liver biopsy in the 1990s a 2-year audit. Aliment Pharmacol Ther 1999 13 603 608.
23. Demetris A Adams D Bellamy C et al. Update of the International Banff schema for liver allograft rejection working recommendations for the histopathologic staging and reporting of chronic rejection. An International Panel. Hepatology 2000 31 792 799.
24. Kidd IM Fox JC Pillay D Charman H Griffiths PD Emery VC. Provision of prognostic information in immunocompromised patients by routine application of the polymerase chain reaction for cytomegalovirus. Transplantation 1993 56 867 871.
25. Papatheodoridis GV Barton SG Andrew D et al. Longitudinal variation in hepatitis C virus (HCV) viraemia and early course of HCV infection after liver transplantation for HCV cirrhosis the role of different immunosuppressive regimens. Gut 1999 45 427 434.
26. Burroughs AK Patch DW Stigliano R Cecilioni L. Protocol biopsies in liver transplantation. Liver Transpl 2003 9 780 781.
27. Charlton M Seaberg E. Impact of immunosuppression and acute rejection on recurrence of hepatitis C results of the national institute of diabetes and digestive and kidney diseases liver transplantation database. Liver Transpl Surg 1999 5 S107 S114.
28. Regev A Molina E Moura R et al. Reliability of histopathologic assessment for the differentiation of recurrent hepatitis C from acute rejection after liver transplantation. Liver Transpl 2004 10 1233.
29. McTaggart RA Terrault NA Vardanian AJ Bostrom A Feng S. Hepatitis C etiology of liver disease is strongly associated with early acute rejection following liver transplantation. Liver Transpl 2004 10 975.
30. Forman LM Lewis JD Berlin JA Feldman HI Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002 122 889 896.
31. Testa G Crippin JS Netto GJ et al. Liver transplantation for hepatitis C recurrence and disease progression in 300 patients. Liver Transpl 2000 6 553 561.
32. Burroughs AK. Induction immunosuppression for patients who underwent transplantation for cirrhosis caused by hepatitis C? The answer is no!. Liver Transpl 2002 8 S47 S49.
33. McCaughan GW Zekry A. Mechanisms of HCV reinfection and allograft damage after liver transplantation. J Hepatol 2004 40 368 374.
34. Gane EJ Portmann BC Naoumov NV et al. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996 334 815 820.
35. Lake JR. The role of immunosuppression in recurrence of hepatitis C. Liver Transpl 2003 9 S63 S66.
36. Neumann UP Berg T Bahra M et al. Long-term outcome of liver transplants for chronic hepatitis C a 10-year follow-up. Transplantation 2004 77 226 231.
37. Prieto M Berenguer M Rayon JM et al. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation relationship with rejection episodes. Hepatology 1999 29 250 256.
38. Casavilla FA Rakela J Kapur S et al. Clinical outcome of patients infected with hepatitis C virus infection on survival after primary liver transplantation under tacrolimus. Liver Transpl Surg 1998 4 448 454.
39. Raimondo ML Dagher L Papatheodoridis GV et al. Long-term mycophenolate mofetil monotherapy in combination with calcineurin inhibitors for chronic renal dysfunction after liver transplantation. Transplantation 2003 75 186 190.
40. Levy G Villamil F Samuel D et al. Results of lis2t, a multicenter, randomized study comparing cyclosporine microemulsion with C2 monitoring and tacrolimus with C0 monitoring in de novo liver transplantation. Transplantation 2004 77 1632 1638.
41. Martin P Busuttil RW Goldstein RM et al. Impact of tacrolimus versus cyclosporine in hepatitis C virus-infected liver transplant recipients on recurrent hepatitis a prospective, randomized trial. Liver Transpl 2004 10 1258 1262.
42. Hunt J Gordon FD Lewis WD et al. Histological recurrence and progression of hepatitis C after orthotopic liver transplantation influence of immunosuppressive regimens. Liver Transpl 2001 7 1056 1063.
43. Stangl JR Carroll KL Illichmann M Striker R. Effect of antimetabolite immunosuppressants on Flaviviridae, including hepatitis C virus. Transplantation 2004 77 562 567.
44. Brillanti S Vivarelli M De Ruvo N et al. Slowly tapering off steroids protects the graft against hepatitis C recurrence after liver transplantation. Liver Transpl 2002 8 884 888.
45. Fasola C Netto G Onaca N et al. A more severe hepatitis C recurrence (HCVR) post liver transplantation (OLT) observed in recent years may be explained by the use of lower-dose corticosteroid (CS) maintenance protocols. Hepatology 2003 38 Suppl 1 226A.
46. Samonakis D Triantos C Thalheimer U et al. Immunosuppression and donor age with respect to severity of HCV recurrence after liver transplantation. Liver Transpl 2005 11 386 395.